Nivolumab
Anal Carcinoma
Instituto do Cancer do Estado de São Paulomonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
45 Active assets in the Anal Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fluorouracilum Federation Francophone de Cancerologie Digestive | Phase 3 | BB |
Carboplatin Dustin Deming | Phase 3 | BB |
Irinotecan University of Cincinnati | Phase 3 | BB |
Muamycin Federation Francophone de Cancerologie Digestive | Phase 3 | BB |
Cis-Diamminedichloroplatinum Ii Federation Francophone de Cancerologie Digestive | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →